Qualigen Therapeutics announces that it has received written notice from the Listing Qualifications Department of the Nasdaq Stock Market informing the Company that it has regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. The letter noted that as a result of the closing bid price of the Company’s common stock having been at least $1.00 per share for a minimum of 10 consecutive business days, the Company has regained compliance with Listing Rule 5550(a)(2) and the matter is now closed.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on QLGN:
- Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule
- Qualigen Therapeutics Announces Pre-IND Feedback from U.S. Food and Drug Administration Regarding QN-302 for the Treatment of G4-Targeted Advanced Solid Tumors
- Qualigen announces pre-IND feedback from FDA on QN-302
- Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split
- Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update